
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Inhibikase Therapeutics, with a price target of $8.00. Jason McCarthy has given his Buy rating
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| IKT | Inhibikase Therapeutics | 1.52 | -0.01 | -0.65% |
| Name | Price | % Change | |
|---|---|---|---|
| $1.52 | -0.65% |

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Inhibikase Therapeutics, with a price target of $8.00. Jason McCarthy has given his Buy rating

Inhibikase Therapeutics ( ($IKT) ) has issued an update. On October 19, 2026, Inhibikase Therapeutics announced that board member Dennis Berman resigned from the board, as well as from his

Inhibikase Therapeutics (IKT) announced the appointment of Scott Wasserman to the company’s board of directors, effective immediately. Concurrent with Wasserman’s appointment, the company also announced the resignation of Dennis Berman

Biotech & Pharma Analysts discuss pulmonary arterial hypertension (PAH) and PAH associated with interstitial lung disease (PH-ILD) (relevant companies GOSS IKT INSM LQDA ROIV UTHR) on an Analyst/Industry conference call

Chardan initiated coverage of Inhibikase Therapeutics (IKT) with a Neutral rating and $1.50 price target The firm sees limited catalysts for the shares to re-rate before the Part A PVR

The latest announcement is out from Inhibikase Therapeutics ( ($IKT) ). On September 8, 2026, Inhibikase Therapeutics updated its corporate presentation to highlight progress and positioning of IKT‑001 as a

Inhibikase Therapeutics, Inc. (IKT) has disclosed a new risk, in the Regulation category. Inhibikase Therapeutics, Inc. faces growing exposure to evolving U.S. legal and regulatory restrictions on relationships with China-based

“During our second quarter and in recent weeks we continued to advance our Phase 3 IMPROVE-PAH study with 26 country regulatory approvals together with the recent initiation of 43 clinical

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Inhibikase Therapeutics and keeping the price target at $8.00. Ram Selvaraju has given his Buy rating due to a

The latest update is out from Inhibikase Therapeutics ( ($IKT) ). On July 29, 2026, Inhibikase Therapeutics entered into an exchange agreement with RA Capital Healthcare Fund under which RA
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Apr 1, 2027TBA | $213.21M | $-0.11 | $0.00 | 0.07 | -3.41 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.